P&G Raises Forecast On Strong First Half, Notes Price Increases As Potential Drag
P&G reports 4% organic growth in its fiscal 2019 Q2, building on a strong Q1 and prompting it to raise full-year organic guidance 1%. CFO Jon Moeller warns, however, possible market volatility and competitor activity related to potential price increases could sink its positive estimate.
You may also be interested in...
P&G beauty division's sales grow on premium skin care lines and despite price increases as health care sales grow 5% on volume, particularly in oral care. Net earnings in latest quarter grow 9% to $2.78bn as results prompt investor activity with share price slipping 2.7% in trading at nearly twice average volume.
Fluocaril and Parogencyl are “well-known” toothpastes that have garnered “strong endorsement from health professionals,” Unilever says. The brands, identified by analysts as potential candidates for sale, are latest in P&G’s ongoing trimming of lower-selling lines.
P&G names Merck KGAA consumer chief Uta Kemmerich-Keil to lead international division of personal health business as it closes on $4.2bn acquisition of German firm's consumer business. Deal closes a month after P&G announced biggest changes to organizational structure in 20 years, including combining personal care and health care into personal health and forming six global units, each headed by a CEO.